Now that the enthusiasm of US regulators for cancer drug accelerated approvals has been well and truly curbed,Incyte Corporation has taken a "business decision" to pull its submissions for parsaclisib for non-Hodgkin’s lymphomas, for which a verdict was expected soon.
The US biotech noted that it was withdrawing the new drug application for parsaclisib for the treatment of relapsed or...



![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

